サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1785719

強直性脊椎炎の世界市場

Ankylosing Spondylitis

出版日
ページ情報
英文 271 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
強直性脊椎炎の世界市場
出版日: 2025年08月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 271 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

強直性脊椎炎の世界市場は2030年までに81億米ドルに達する見込み

2024年に60億米ドルと推定される強直性脊椎炎の世界市場は、2024～2030年の分析期間においてCAGR 5.2%で成長し、2030年には81億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるTNF阻害剤薬剤クラス別は、CAGR6.1%を記録し、分析期間終了時には44億米ドルに達すると予測されます。NSAIDs薬剤クラス別の成長率は、分析期間中CAGR 4.7%と推定されます。

米国市場は16億米ドルと推定、中国はCAGR 8.4％で成長予測

米国の強直性脊椎炎市場は2024年に16億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と5.3％と予測されています。欧州では、ドイツがCAGR 3.4%で成長すると予測されています。

世界の強直性脊椎炎市場- 主要動向と促進要因のまとめ

強直性脊椎炎が世界的に重大な健康問題になりつつあるのはなぜか？

主に脊椎と仙腸関節に影響を及ぼす慢性炎症性疾患である強直性脊椎炎（AS）は、その衰弱させる性質と生活の質への長期的な影響から、世界の健康上の重大な懸念として認知されつつあります。ASは主に若年成人に発症し、症状は10代後半から20代前半に始まることが多いです。慢性疼痛、こわばり、潜在的な脊椎固定を特徴とするこの疾患の進行性の性質は、症状を管理し合併症を予防するための効果的な治療介入の必要性を強調しています。さらに、世界中で強直性脊椎炎の有病率が上昇していることから、的を絞った治療オプションに対する需要が高まっています。ASの正確な原因は未だ不明であるが、遺伝的素因、特にHLA-B27遺伝子の存在が主要な危険因子として同定されています。このことは、AS患者に対してオーダーメイドの治療戦略を可能にする精密医療アプローチの進歩を促しています。さらに、生産性の低下やヘルスケアコストなど、この疾患の社会的・経済的負担が大きいことから、効果的な治療法へのアクセスを改善することへの関心が高まっています。

AS治療開発の原動力となっている進歩とは？

強直性脊椎炎の治療状況は、生物学的製剤や標的合成疾患修飾性抗リウマチ薬（DMARDs）の進歩に牽引され、大きく発展してきました。アダリムマブやインフリキシマブのような腫瘍壊死因子（TNF）阻害薬は、炎症を抑え、疾患の進行を遅らせ、患者の転帰を改善することにより、ASの治療を大きく変えました。セクキヌマブやイキセキズマブを含むインターロイキン（IL）-17阻害剤の導入は、特にTNF阻害剤に反応しない患者に対する治療の選択肢をさらに広げています。自己皮下注射や徐放性製剤などのドラッグデリバリーシステムの革新は、患者のコンプライアンスと利便性を向上させました。さらに、磁気共鳴画像法（MRI）や遺伝子検査などの診断ツールの進歩により、ASの早期発見が容易になり、タイムリーな介入とより良い疾患管理が可能となっています。ヤヌスキナーゼ（JAK）阻害剤のような新規治療標的に関する継続的な研究は、近い将来、効果的な治療選択肢の幅を広げる可能性を秘めています。

地域力学は市場成長にどのような影響を与えているか？

強直性脊椎炎市場は、疾患有病率、ヘルスケアインフラ、先進治療へのアクセスなどの違いにより、大きな地域差が見られます。北米は、自己免疫疾患の高い有病率、強固なヘルスケアシステム、研究開発への多額の投資によって市場を独占しています。同地域はまた、有利な償還政策や先進的な生物学的製剤の普及からも恩恵を受けています。欧州は、早期診断と革新的治療を標準治療プロトコールに組み入れることに強い重点を置いており、これに続いています。ドイツ、英国、フランスなどの国々では、リウマチ科のネットワークが確立されており、より良い疾患管理と患者の転帰が保証されています。アジア太平洋地域では、疾患に対する意識の高まり、ヘルスケアへのアクセスの改善、可処分所得の増加により、市場が急速に拡大しています。中国やインドなどの新興国では、医療インフラを強化する政府のイニシアティブに支えられ、生物学的製剤の採用が拡大しています。一方、ラテンアメリカや中東では、価格や認知度に関する課題は残るもの、先進的な治療が徐々に受け入れられています。

強直性脊椎炎市場の成長の原動力は？

強直性脊椎炎市場の成長は、自己免疫疾患や炎症性疾患の有病率の上昇、生物学的療法の進歩、早期診断の重要性に対する意識の高まりなど、いくつかの要因によってもたらされます。TNF阻害薬やIL-17阻害薬が第一選択治療薬として採用されるようになったことで、患者の予後が大幅に改善し、市場の拡大に拍車がかかっています。さらに、JAK阻害薬やその他の新規生物学的製剤を含む次世代療法の開発により、AS管理におけるアンメットニーズに対応しつつあります。自己注射など、より便利で効果的な治療法を求める消費者の需要が、ドラッグデリバリーシステムの技術革新に拍車をかけています。特に新興市場においては、ヘルスケアへのアクセスや医療費の負担を改善するための地域政府の取り組みが、先進的な治療法の採用をさらに後押ししています。さらに、遠隔医療や遠隔モニタリングを含むデジタルヘルスツールの統合は、より良い疾病管理と治療アドヒアランスを促進しています。これらの要因が総合的に、強直性脊椎炎市場の堅調な成長軌道と、この慢性疾患の世界の負担に対処する上で重要な役割を浮き彫りにしています。

セグメント

薬剤クラス（TNF阻害薬クラス、非ステロイド性抗炎症薬クラス、その他薬剤クラス別）、流通チャネル（病院薬局、小売薬局、その他流通チャネル）

調査対象企業の例

  • AbbVie, Inc.
  • Akeso Biopharma Co., Ltd.
  • Amgen, Inc.
  • Coherus Biosciences, Inc.
  • Eli Lilly and Company
  • Johnson & Johnson Innovative Medicine UK
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Trinity Biotech PLC
  • UCB SA
  • ViennaLab Diagnostics GmbH
  • Zydus Lifesciences Limited

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29167

Global Ankylosing Spondylitis Market to Reach US$8.1 Billion by 2030

The global market for Ankylosing Spondylitis estimated at US$6.0 Billion in the year 2024, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. TNF Inhibitors Drug Class, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the NSAIDs Drug Class segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 8.4% CAGR

The Ankylosing Spondylitis market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Ankylosing Spondylitis Market - Key Trends & Drivers Summarized

Why Is Ankylosing Spondylitis Becoming a Critical Global Health Concern?

Ankylosing spondylitis (AS), a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, is gaining recognition as a significant global health concern due to its debilitating nature and long-term impact on quality of life. AS primarily affects young adults, with symptoms often beginning in the late teens or early twenties. The progressive nature of the disease, characterized by chronic pain, stiffness, and potential spinal fusion, underscores the need for effective therapeutic interventions to manage symptoms and prevent complications. Moreover, the rising prevalence of ankylosing spondylitis worldwide has led to increased demand for targeted treatment options. While the exact cause of AS remains unclear, genetic predisposition, particularly the presence of the HLA-B27 gene, has been identified as a major risk factor. This has prompted advancements in precision medicine approaches, enabling tailored treatment strategies for individuals with AS. Additionally, the societal and economic burden of the disease, including loss of productivity and healthcare costs, has heightened the focus on improving access to effective therapies.

What Advancements Are Driving the Development of AS Treatments?

The treatment landscape for ankylosing spondylitis has evolved significantly, driven by advancements in biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs). Tumor necrosis factor (TNF) inhibitors, such as adalimumab and infliximab, have been pivotal in transforming the management of AS by reducing inflammation, slowing disease progression, and improving patient outcomes. The introduction of interleukin (IL)-17 inhibitors, including secukinumab and ixekizumab, has further expanded treatment options, particularly for patients who do not respond to TNF inhibitors. Innovations in drug delivery systems, such as self-administered subcutaneous injections and extended-release formulations, have improved patient compliance and convenience. Furthermore, advancements in diagnostic tools, including magnetic resonance imaging (MRI) and genetic testing, are facilitating earlier detection of AS, enabling timely intervention and better disease management. Ongoing research into novel therapeutic targets, such as Janus kinase (JAK) inhibitors, holds promise for expanding the range of effective treatment options in the near future.

How Are Regional Dynamics Influencing Market Growth?

The ankylosing spondylitis market exhibits significant regional variations, influenced by differences in disease prevalence, healthcare infrastructure, and access to advanced treatments. North America dominates the market, driven by a high prevalence of autoimmune diseases, robust healthcare systems, and substantial investments in research and development. The region also benefits from favorable reimbursement policies and widespread availability of advanced biologic therapies. Europe follows closely, with a strong focus on early diagnosis and the integration of innovative treatments into standard care protocols. Countries such as Germany, the UK, and France have well-established rheumatology networks, ensuring better disease management and patient outcomes. In the Asia-Pacific region, the market is expanding rapidly due to increasing disease awareness, improving healthcare access, and rising disposable incomes. Emerging economies such as China and India are witnessing growing adoption of biologic therapies, supported by government initiatives to enhance healthcare infrastructure. Meanwhile, Latin America and the Middle East are gradually embracing advanced treatments, although challenges related to affordability and awareness persist.

What Is Driving Growth in the Ankylosing Spondylitis Market?

The growth in the ankylosing spondylitis market is driven by several factors, including the rising prevalence of autoimmune and inflammatory diseases, advancements in biologic therapies, and increasing awareness of the importance of early diagnosis. The growing adoption of TNF inhibitors and IL-17 inhibitors as first-line treatments has significantly improved patient outcomes, fueling market expansion. Additionally, the development of next-generation therapies, including JAK inhibitors and other novel biologics, is addressing unmet needs in AS management. Consumer demand for more convenient and effective treatment options, such as self-administered injections, has spurred innovation in drug delivery systems. Regional government initiatives to improve healthcare access and affordability, particularly in emerging markets, are further driving the adoption of advanced therapies. Moreover, the integration of digital health tools, including telemedicine and remote monitoring, is facilitating better disease management and treatment adherence. These factors collectively highlight the robust growth trajectory of the ankylosing spondylitis market and its critical role in addressing the global burden of this chronic condition.

SCOPE OF STUDY:

The report analyzes the Ankylosing Spondylitis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (TNF Inhibitors Drug Class, NSAIDs Drug Class, Other Drug Classes); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie, Inc.
  • Akeso Biopharma Co., Ltd.
  • Amgen, Inc.
  • Coherus Biosciences, Inc.
  • Eli Lilly and Company
  • Johnson & Johnson Innovative Medicine UK
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Trinity Biotech PLC
  • UCB SA
  • ViennaLab Diagnostics GmbH
  • Zydus Lifesciences Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Ankylosing Spondylitis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Ankylosing Spondylitis Propels Demand for Early Diagnosis and Treatment Solutions
    • Growing Awareness About Autoimmune Disorders Expands Addressable Market Opportunity for AS Therapeutics
    • Advancements in Biologics and Targeted Therapies Drive Innovation in Ankylosing Spondylitis Treatment
    • Rising Adoption of Biosimilars Spurs Market Growth for Cost-Effective Ankylosing Spondylitis Treatment Options
    • Increased Focus on Personalized Medicine Generates Demand for Tailored AS Treatment Approaches
    • Integration of Digital Health & Telemedicine Improves Accessibility and Compliance in AS Management
    • Growing Role of Lifestyle and Physiotherapy Interventions Sustains Market Growth for Holistic AS Care
    • Expanding Application of Artificial Intelligence in Disease Diagnosis and Drug Discovery Accelerates AS Market Developments
    • Regulatory Support for Fast-Track Approvals Expedites Market Entry of Innovative AS Therapies
    • Patient Advocacy and Support Groups Strengthen Market Dynamics Through Awareness and Education Initiatives
    • Challenges Related to High Cost of Biologic Therapies Impact Market Penetration in Low-Income Regions
    • Rising Healthcare Expenditure and Insurance Coverage Expansion Drive Adoption of AS Treatment Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ankylosing Spondylitis Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for TNF Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for TNF Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for TNF Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for NSAIDs Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for NSAIDs Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for NSAIDs Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Ankylosing Spondylitis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Ankylosing Spondylitis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Ankylosing Spondylitis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Ankylosing Spondylitis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION